Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pregnant women's presumed inclusion in clinical research called for in HHS proposal.

This article was originally published in The Tan Sheet

Executive Summary

PREGNANT WOMEN's PRESUMED INCLUSION IN CLINICAL RESEARCH is called for by HHS in an advance notice of proposed rulemaking published in the May 20 Federal Register. The proposed rule "institutes a policy of presumed opportunity for inclusion of pregnant women in research in place of one of presumed exclusion," HHS states. In other words, pregnant women should be allowed to be participants in clinical trials unless there are compelling reasons to prevent their inclusion. HHS invites comments on the proposed rule, which modifies 45 CFR 46 Subpart B, until Aug. 18.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088475

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel